IP Library Patent Application 14991326
Patent Application
App. No. 14/991,326

METHOD FOR INHIBITING PLATELET AGGREGATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/991,326
Abstract

A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of between about 25 μg/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 μg/kg/min, wherein the active drug is tirofiban or a salt thereof.

Claims (20)

1 . A method for reducing the risk of thrombosis, thromboembolism or reocclusion in a patient after surgery on peripheral arteries, comprising administering to the patient a bolus injection of about 25 μg/kg of tirofiban or salt thereof to inhibit platelet aggregation.

2 . The method of claim wherein the patient underwent peripheral arterial intervention.

3 . The method of claim 1 wherein the platelet aggregation occurs in peripheral arteries.

4 . The method of claim 1 wherein the bolus injection is at least 20 μg/kg of tirofiban or salt thereof.

5 . The method of claim 1 , wherein the salt is tirofiban hydrochloride.

6 . The method of claim 1 , further comprising administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of tirofiban or salt thereof to inhibit platelet aggregation, in an amount of about 0.15 μg/kg/min.

7 . The method of claim 6 wherein the intravenous infusion is about 12 hours.

8 . A method of preventing platelet thrombosis, thromboembolism or reocclusion after surgery on peripheral arteries in a patient comprising administering to the patient a bolus injection of tirofiban or salt thereof, in amounts sufficient to inhibit platelet aggregation.

9 . The method of claim 8 wherein the patient underwent peripheral arterial intervention.

10 . The method of claim 8 wherein the platelet aggregation occurs in peripheral arteries.

11 . The method of claim 8 wherein the bolus injection is at least 20 μg/kg of tirofiban or salt thereof.

12 . The method of claim 8 , wherein the salt is tirofiban hydrochloride.

13 . The method of claim 8 , further comprising administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of tirofiban or salt thereof to inhibit platelet aggregation, in an amount of about 0.15 μg/kg/min.

14 . The method of claim 8 wherein the intravenous infusion is about 12 hours.

15 . A method of preventing myocardial infarction in a patient after surgery on peripheral arteries in a patient comprising administering to the patient a bolus injection of tirofiban or salt thereof.

16 . The method of claim 15 wherein the patient underwent peripheral arterial intervention.

17 . The method of claim 15 wherein the bolus injection is at least 20 μg/kg of tirofiban or salt thereof.

18 . The method of claim 15 , wherein the salt is tirofiban hydrochloride.

19 . The method of claim 15 , further comprising administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of tirofiban or salt thereof to inhibit platelet aggregation, in an amount of about 0.15 μg/kg/min.

20 . The method of claim 15 wherein the intravenous infusion is about 12 hours.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Nov 22, 2017
From: CROWN CAPITAL FUND IV MANAGEMENT INC.
To: MEDICURE INTERNATIONAL INC.
Reel/Frame 044197/0765 →
SECURITY INTEREST Recorded Dec 22, 2016
From: MEDICURE INTERNATIONAL INC.
To: CROWN CAPITAL FUND IV MANAGEMENT INC.
Reel/Frame 040745/0950 →